earnings
confidence high
sentiment neutral
materiality 0.80
Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer
Arcus Biosciences, Inc.
2025-FY EPS reported
-$3.29
revenue$247,000,000
- Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.
- Casdatifan 100mg QD in late-line ccRCC: confirmed ORR 45.2%, median PFS 15.1 months (Jan 30, 2026 cut).
- Full-year 2026 GAAP revenue guidance $45-55M; R&D expenses expected to decrease meaningfully.
- Phase 3 PEAK-1 (casdatifan + cabozantinib) enrolling globally; 1L Phase 3 planned by end 2026.
- First inflammation program (oral MRGPRX2 antagonist) to enter clinic in 2026; oral TNF inhibitor in late 2026/early 2027.